Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
November 30 2017 - 7:00AM
Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage
biopharmaceutical company engaged in the research and development
of novel anti-infective agents to treat serious infections, with a
focus on the pleuromutilin class of antibiotics, today announced
that members of the company’s management team will participate in
the Guggenheim Securities 5th Annual Boston Healthcare Conference
on Wednesday, December 13, 2017. The conference is being held at
the InterContinental Boston hotel in Boston, Massachusetts.
About Nabriva Therapeutics plcNabriva
Therapeutics is a biopharmaceutical company engaged in the research
and development of new medicines to treat serious bacterial
infections, with a focus on the pleuromutilin class of antibiotics.
Nabriva Therapeutics’ medicinal chemistry expertise has enabled
targeted discovery of novel pleuromutilins, including both
intravenous and oral formulations. Nabriva Therapeutics’ lead
product candidate, lefamulin, is a novel semi-synthetic
pleuromutilin antibiotic with the potential to be the
first-in-class available for systemic administration in humans. The
company believes that lefamulin is the first antibiotic with a
novel mechanism of action to have reached late-stage clinical
development in more than a decade. Nabriva has announced positive
topline data for lefamulin from the first of its two global,
registrational Phase 3 clinical trials evaluating lefamulin in
patients with moderate to severe community-acquired bacterial
pneumonia (CABP). Nabriva Therapeutics believes lefamulin is
well-positioned for use as a first-line empiric monotherapy for the
treatment of moderate to severe CABP due to its novel mechanism of
action, targeted spectrum of activity, resistance profile,
achievement of substantial drug concentration in lung tissue and
fluid, oral and IV formulations and a favorable tolerability
profile, with the results of the LEAP 1 trial showing a rate of
treatment-emergent adverse events comparable to moxifloxacin with
or without linezolid. Nabriva Therapeutics intends to further
pursue development of lefamulin for additional indications and is
developing a formulation of lefamulin appropriate for pediatric
use.
Nabriva Therapeutics owns exclusive, worldwide
rights to lefamulin, which is protected by composition of matter
patents issued in the United States, Europe and Japan.
Forward-Looking StatementsAny statements in
this press release about future expectations, plans and prospects
for Nabriva, including but not limited to statements about the
development of Nabriva’s product candidates, such as plans for the
design, conduct and timelines of Nabriva’s ongoing Phase 3 clinical
trial of lefamulin for CABP, the clinical utility of lefamulin for
CABP and Nabriva’s plans for filing of regulatory approvals and
efforts to bring lefamulin to market, the market opportunity for
and the potential market acceptance of lefamulin for CABP, the
development of lefamulin for additional indications, the
development of additional formulations of lefamulin, plans to
pursue research and development of other product candidates, the
sufficiency of Nabriva’s existing cash resources and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, availability and timing of data from clinical trials,
whether results of early clinical trials or trials in different
disease indications will be indicative of the results of ongoing or
future trials, whether results of Nabriva’s first Phase 3 clinical
trial of lefamulin will be indicative of the results for its second
Phase 3 clinical trial of lefamulin, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of product
candidates including lefamulin for use as a first-line empiric
monotherapy for the treatment of moderate to severe CABP, the
sufficiency of cash resources and need for additional financing and
such other important factors as are set forth under the caption
“Risk Factors” in Nabriva’s annual and quarterly reports on file
with the U.S. Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Nabriva’s views as of the date of this release. Nabriva anticipates
that subsequent events and developments will cause its views to
change. However, while Nabriva may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva’s views as of any date subsequent to the date
of this release.
CONTACTS:
FOR INVESTORSDave GarrettNabriva Therapeutics
plcdavid.garrett@nabriva.com 610-816-6657
FOR MEDIABenjamin NavonPure
Communicationsbnavon@purecommunications.com 617-337-4166
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024